Shopping Cart
- Remove All
- Your shopping cart is currently empty
CML-IN-1, also known as compound 7 and compound 4, is a potent anticancer agent that demonstrates a strong induced-apoptosis effect in the human chronic myeloid leukemia (CML) cell line K562. It diminishes protein phosphorylation within the PI3K/Akt signaling pathway to exert its effects and suppresses cell proliferation through the inhibition of the MEK/ERK signaling pathway in colorectal cancer [1] [2].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 6-8 weeks | |
50 mg | $1,980 | 6-8 weeks | |
100 mg | $2,500 | 6-8 weeks |
Description | CML-IN-1, also known as compound 7 and compound 4, is a potent anticancer agent that demonstrates a strong induced-apoptosis effect in the human chronic myeloid leukemia (CML) cell line K562. It diminishes protein phosphorylation within the PI3K/Akt signaling pathway to exert its effects and suppresses cell proliferation through the inhibition of the MEK/ERK signaling pathway in colorectal cancer [1] [2]. |
In vitro | CML-IN-1 (compound 7) demonstrated minimal cytotoxicity and enhanced bioactivity in cellular assays (K562, IC50: 0.038 µM) [1]. CML-IN-1 (compound 4) significantly inhibited HCT116 cell proliferation with IC50 values of 8.04 ± 0.94 µM at 48 hours and 5.52 ± 0.42 µM at 72 hours, suppressed colony formation, migration, and invasion in a dose-dependent manner, induced apoptosis, caused cell cycle arrest at the G2/M phase, and inhibited MEK/ERK signaling pathway activation [2]. |
Molecular Weight | 540.58 |
Formula | C21H23F3N8O2S2 |
Cas No. | 2235393-30-1 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.